EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Diabetic Retinopathy - Pipeline Review, H1 2015

  • ID: 3308765
  • Report
  • May 2015
  • 180 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acucela Inc.
  • Charlesson LLC.
  • IMMD Inc.
  • MacuCLEAR, Inc.
  • Promedior, Inc.
  • Stelic Institute & Co.
  • MORE
Diabetic Retinopathy - Pipeline Review, H1 2015

Summary

This, ‘Diabetic Retinopathy - Pipeline Review, H1 2015’, provides an overview of the Diabetic Retinopathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acucela Inc.
  • Charlesson LLC.
  • IMMD Inc.
  • MacuCLEAR, Inc.
  • Promedior, Inc.
  • Stelic Institute & Co.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Diabetic Retinopathy Overview
Therapeutics Development
Pipeline Products for Diabetic Retinopathy - Overview
Pipeline Products for Diabetic Retinopathy - Comparative Analysis
Diabetic Retinopathy - Therapeutics under Development by Companies
Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes
Diabetic Retinopathy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Diabetic Retinopathy - Products under Development by Companies
Diabetic Retinopathy - Products under Investigation by Universities/Institutes
Diabetic Retinopathy - Companies Involved in Therapeutics Development
Acucela Inc.
Aerpio Therapeutics, Inc.
Angstrom Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Aprogen, Inc.
BioDiem Ltd
Biomar Microbial Technologies
Charlesson LLC.
Crinetics Pharmaceuticals, Inc.
Dimerix Bioscience Pty Ltd
EyeGene, Inc.
Foresee Pharmaceuticals, LLC
GTx, Inc.
Icon Bioscience, Inc.
IMMD Inc.
Islet Sciences, Inc.
Kowa Company, Ltd.
LegoChem Biosciences, Inc
MacuCLEAR, Inc.
MingSight Pharmaceuticals
Molecular Design International, Inc.
OcuCure Therapeutics, Inc.
Ohr Pharmaceutical Inc.
PanOptica, Inc.
Promedior, Inc.
R-Tech Ueno, Ltd.
Resolvyx Pharmaceuticals, Inc
RestorGenex Corporation
Sirnaomics, Inc.
Stelic Institute & Co.
Stemedica Cell Technologies, Inc.
Targazyme, Inc.
ThromboGenics NV
TWi Pharmaceuticals, Inc.
Diabetic Retinopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
49-B - Drug Profile
A-6 - Drug Profile
A-717 - Drug Profile
AC-301 - Drug Profile
AKB-9778 - Drug Profile
ALG-1001 - Drug Profile
AP-202 - Drug Profile
ATL-1103 - Drug Profile
BDM-E - Drug Profile
Beta-LGND2 - Drug Profile
CLT-01001 - Drug Profile
CLT-01007 - Drug Profile
CLT-01012 - Drug Profile
cyclosporine - Drug Profile
Cyndacel-M - Drug Profile
DG-3173 - Drug Profile
DMX-200 - Drug Profile
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile
DT-23552 - Drug Profile
E-1086 - Drug Profile
EG-Mirotin - Drug Profile
emixustat hydrochloride - Drug Profile
FP-008 - Drug Profile
IB-09A0133 - Drug Profile
IMD-0354 - Drug Profile
JP-153 - Drug Profile
L-779976 - Drug Profile
LCB-030110 - Drug Profile
Lycium Anti-Angiogenic Proteoglycan - Drug Profile
MC-4001 - Drug Profile
Mesenchymal Stem Cells - Drug Profile
MS-553 - Drug Profile
OC-10X - Drug Profile
ocriplasmin (recombinant) - Drug Profile
OLX-302 - Drug Profile
PAN-90806 - Drug Profile
PRM-167 - Drug Profile
Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile
Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile
RES-529 - Drug Profile
ripasudil - Drug Profile
RTU-007 - Drug Profile
RTU-1096 - Drug Profile
RX-20001 - Drug Profile
squalamine lactate - Drug Profile
Stem Cell Therapy for Diabetic Retinopathy - Drug Profile
STNM-1510 - Drug Profile
STP-601 - Drug Profile
TZ-101 - Drug Profile
V-1932 - Drug Profile
Diabetic Retinopathy - Recent Pipeline Updates
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Diabetic Retinopathy, H1 2015
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Diabetic Retinopathy - Pipeline by Acucela Inc., H1 2015
Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Angstrom Pharmaceuticals, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H1 2015
Diabetic Retinopathy - Pipeline by Aprogen, Inc., H1 2015
Diabetic Retinopathy - Pipeline by BioDiem Ltd, H1 2015
Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2015
Diabetic Retinopathy - Pipeline by Charlesson LLC., H1 2015
Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015
Diabetic Retinopathy - Pipeline by EyeGene, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015
Diabetic Retinopathy - Pipeline by GTx, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Icon Bioscience, Inc., H1 2015
Diabetic Retinopathy - Pipeline by IMMD Inc., H1 2015
Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H1 2015
Diabetic Retinopathy - Pipeline by LegoChem Biosciences, Inc, H1 2015
Diabetic Retinopathy - Pipeline by MacuCLEAR, Inc., H1 2015
Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H1 2015
Diabetic Retinopathy - Pipeline by Molecular Design International, Inc., H1 2015
Diabetic Retinopathy - Pipeline by OcuCure Therapeutics, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc., H1 2015
Diabetic Retinopathy - Pipeline by PanOptica, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Promedior, Inc., H1 2015
Diabetic Retinopathy - Pipeline by R-Tech Ueno, Ltd., H1 2015
Diabetic Retinopathy - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015
Diabetic Retinopathy - Pipeline by RestorGenex Corporation, H1 2015
Diabetic Retinopathy - Pipeline by Sirnaomics, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Stelic Institute & Co., H1 2015
Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H1 2015
Diabetic Retinopathy - Pipeline by Targazyme, Inc., H1 2015
Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2015
Diabetic Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Diabetic Retinopathy Therapeutics - Recent Pipeline Updates, H1 2015
Diabetic Retinopathy - Dormant Projects, H1 2015
Diabetic Retinopathy - Dormant Projects (Contd..1), H1 2015
Diabetic Retinopathy - Dormant Projects (Contd..2), H1 2015
Diabetic Retinopathy - Dormant Projects (Contd..3), H1 2015
Diabetic Retinopathy - Dormant Projects (Contd..4), H1 2015
Diabetic Retinopathy - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Diabetic Retinopathy, H1 2015
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Acucela Inc.
Aerpio Therapeutics, Inc.
Angstrom Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Aprogen, Inc.
BioDiem Ltd
Biomar Microbial Technologies
Charlesson LLC.
Crinetics Pharmaceuticals, Inc.
Dimerix Bioscience Pty Ltd
EyeGene, Inc.
Foresee Pharmaceuticals, LLC
GTx, Inc.
Icon Bioscience, Inc.
IMMD Inc.
Islet Sciences, Inc.
Kowa Company, Ltd.
LegoChem Biosciences, Inc
MacuCLEAR, Inc.
MingSight Pharmaceuticals
Molecular Design International, Inc.
OcuCure Therapeutics, Inc.
Ohr Pharmaceutical Inc.
PanOptica, Inc.
Promedior, Inc.
R-Tech Ueno, Ltd.
Resolvyx Pharmaceuticals, Inc
RestorGenex Corporation
Sirnaomics, Inc.
Stelic Institute & Co.
Stemedica Cell Technologies, Inc.
Targazyme, Inc.
ThromboGenics NV
TWi Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll